Aliases & Classifications for Ureteral Obstruction

MalaCards integrated aliases for Ureteral Obstruction:

Name: Ureteral Obstruction 12 56 45 15

External Ids:

Disease Ontology 12 DOID:5199
ICD9CM 36 593.4
MeSH 45 D014517
UMLS 74 C0029866

Summaries for Ureteral Obstruction

MalaCards based summary : Ureteral Obstruction is related to renal fibrosis and hydronephrosis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are TGF-Beta Pathway and p70S6K Signaling. The drugs Tamsulosin and Silodosin have been mentioned in the context of this disorder. Affiliated tissues include kidney, cervix and tongue, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ureteral Obstruction

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 renal fibrosis 31.6 AGTR1 BMP7 TGFB1
2 hydronephrosis 31.2 AQP2 SLC12A1 TGFB1
3 urinary tract obstruction 30.4 AQP2 PTGS2 TGFB1
4 chronic kidney failure 30.3 AGTR1 EPO PTGS2 TGFB1
5 kidney disease 30.1 AGTR1 AGTR2 AQP2 BMP7 EPO TGFB1
6 colitis 29.7 CTNNB1 IL10 NOS2 PTGS2
7 familial adenomatous polyposis 29.4 CTNNB1 PTGS2 TP53
8 endometriosis 10.6
9 retroperitoneal fibrosis 10.5
10 juvenile myasthenia gravis 10.4 IL10 TGFB1
11 aortic aneurysm 10.3
12 vesicoureteral reflux 1 10.3
13 inflammatory bowel disease 25, autosomal recessive 10.3 IL10 TGFB1
14 familial vesicoureteral reflux 10.2 AGTR2 TGFB1
15 cystitis 10.2
16 anuria 10.2
17 leukoregulin 10.2 PTGS2 TGFB1
18 end stage renal failure 10.2 AGTR1 EPO TGFB1
19 posterior urethral valves 10.2 AGTR1 AGTR2 TGFB1
20 pyelonephritis 10.2
21 actinomycosis 10.2
22 adult hepatocellular carcinoma 10.2 CTNNB1 TP53
23 aortic aneurysm, familial abdominal, 1 10.2
24 fibrosclerosis, multifocal 10.2
25 malakoplakia 10.2
26 chagas disease 10.2 IL10 NOS2 TGFB1
27 leptospirosis 10.2 IL10 SLC12A1 SLC9A3
28 lymphoma 10.2
29 obstructive nephropathy 10.2
30 pancreatitis 10.2
31 proteasome-associated autoinflammatory syndrome 1 10.1 IL10 NOS2 PTGS2
32 sarcoma 10.1
33 transitional cell carcinoma 10.1
34 lipomatosis 10.1
35 pelvic lipomatosis 10.1
36 hypoxia 10.1
37 protoplasmic astrocytoma 10.1 PTGS2 TP53
38 esophagitis 10.1 PTGS2 TGFB1 TP53
39 renal artery disease 10.1 AGTR1 EPO
40 breast cancer 10.1
41 prostate cancer 10.1
42 prostate cancer, hereditary, 8 10.1
43 prostate cancer, hereditary, 6 10.1
44 crohn's disease 10.1
45 leukemia 10.1
46 inguinal hernia 10.1
47 thrombosis 10.1
48 henoch-schoenlein purpura 10.1
49 adenocarcinoma 10.1
50 ischemia 10.1

Graphical network of the top 20 diseases related to Ureteral Obstruction:



Diseases related to Ureteral Obstruction

Symptoms & Phenotypes for Ureteral Obstruction

GenomeRNAi Phenotypes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

27 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.74 TGFB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.74 AGTR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.74 TGFB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.74 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.74 TGFB1 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.74 AGTR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.74 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.74 TGFB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.74 TGFB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 AGTR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 TGFB1 TP53
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.74 AGTR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.74 TGFB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.74 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.74 TP53
16 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.74 TGFB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.74 AGTR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.74 AGTR1 TGFB1 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.74 TP53
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 AGTR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.74 TGFB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.74 AGTR1

MGI Mouse Phenotypes related to Ureteral Obstruction:

47 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.51 AGTR1 AGTR2 BMP7 CTNNB1 EPO IL10
2 homeostasis/metabolism MP:0005376 10.44 AGTR1 AGTR2 AQP2 CTNNB1 EPO IL10
3 behavior/neurological MP:0005386 10.39 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 IL10
4 mortality/aging MP:0010768 10.38 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 EPO
5 growth/size/body region MP:0005378 10.37 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 IL10
6 hematopoietic system MP:0005397 10.36 AGTR1 AQP2 BMP7 CTNNB1 EPO IL10
7 cellular MP:0005384 10.34 AGTR2 CTNNB1 EPO IL10 LRP2 NOS2
8 immune system MP:0005387 10.34 AGTR1 BMP7 CTNNB1 EPO IL10 LRP2
9 endocrine/exocrine gland MP:0005379 10.31 AGTR2 BMP7 CTNNB1 IL10 LRP2 NOS2
10 digestive/alimentary MP:0005381 10.28 AGTR2 BMP7 CTNNB1 IL10 LRP2 NOS2
11 integument MP:0010771 10.25 AGTR2 AQP2 BMP7 CTNNB1 EPO IL10
12 embryo MP:0005380 10.23 BMP7 CTNNB1 EPO IL10 LRP2 PTGS2
13 nervous system MP:0003631 10.18 AGTR1 AGTR2 BMP7 CTNNB1 IL10 LRP2
14 adipose tissue MP:0005375 10.16 AGTR1 AGTR2 NOS2 PTGS2 SLC9A3 TGFB1
15 muscle MP:0005369 10.16 AGTR2 CTNNB1 EPO IL10 NOS2 NOX4
16 craniofacial MP:0005382 10.14 BMP7 CTNNB1 IL10 LRP2 NOS2 TGFB1
17 renal/urinary system MP:0005367 10.13 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 LRP2
18 liver/biliary system MP:0005370 10.04 CTNNB1 EPO IL10 NOS2 PTGS2 TGFB1
19 reproductive system MP:0005389 10 AQP2 BMP7 CTNNB1 IL10 LRP2 NOS2
20 neoplasm MP:0002006 9.98 AGTR2 CTNNB1 IL10 NOS2 PTGS2 TGFB1
21 no phenotypic analysis MP:0003012 9.91 CTNNB1 IL10 LRP2 NOX4 PTGS2 SPHK2
22 respiratory system MP:0005388 9.85 BMP7 CTNNB1 EPO IL10 LRP2 NOS2
23 skeleton MP:0005390 9.7 AGTR2 BMP7 CTNNB1 EPO IL10 LRP2
24 vision/eye MP:0005391 9.23 BMP7 CTNNB1 IL10 LRP2 NOS2 PTGS2

Drugs & Therapeutics for Ureteral Obstruction

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4,Not Applicable 106133-20-4 129211
2
Silodosin Approved Phase 4 160970-54-7
3 Adrenergic alpha-1 Receptor Antagonists Phase 4,Not Applicable
4 Adrenergic Antagonists Phase 4,Not Applicable
5 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
6 Muscarinic Antagonists Phase 4,Not Applicable
7 Adrenergic alpha-Antagonists Phase 4,Not Applicable
8 Cholinergic Antagonists Phase 4,Not Applicable
9 Cholinergic Agents Phase 4,Not Applicable
10 Adrenergic Agents Phase 4,Phase 2,Not Applicable
11 Tolterodine tartrate Phase 4 124937-52-6
12 Fibrin Tissue Adhesive Phase 3
13 Hemostatics Phase 3
14 Coagulants Phase 3
15
Iodine Approved, Investigational Phase 2 7553-56-2 807
16
Triclosan Approved, Investigational Phase 2 3380-34-5 5564
17
Lidocaine Approved, Vet_approved Phase 2,Not Applicable 137-58-6 3676
18
leucovorin Approved Phase 2 58-05-9 143 6006
19
Floxuridine Approved Phase 2 50-91-9 5790
20
Fluorouracil Approved Phase 2 51-21-8 3385
21
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
22
Mirabegron Approved Phase 2 223673-61-8 9865528
23
Gemcitabine Approved Phase 2 95058-81-4 60750
24
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
26 Anesthetics Phase 2,Not Applicable
27 Anti-Infective Agents Phase 2,Not Applicable
28 Hypolipidemic Agents Phase 2
29 Anti-Infective Agents, Local Phase 2
30 Lipid Regulating Agents Phase 2
31 Antimetabolites Phase 2
32 Peripheral Nervous System Agents Phase 2,Not Applicable
33 Anesthetics, Local Phase 2,Not Applicable
34 Diuretics, Potassium Sparing Phase 2,Not Applicable
35 Central Nervous System Depressants Phase 2,Not Applicable
36 Sodium Channel Blockers Phase 2,Not Applicable
37 Anti-Arrhythmia Agents Phase 2,Not Applicable
38 Immunologic Factors Phase 2
39 Calcium, Dietary Phase 2
40 Trace Elements Phase 2
41 Micronutrients Phase 2
42 Vitamin B9 Phase 2
43 Antidotes Phase 2
44 Antimetabolites, Antineoplastic Phase 2
45 Vitamins Phase 2
46 Protective Agents Phase 2
47 Cola Phase 2
48 Liver Extracts Phase 2
49 Nutrients Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
3 Functional MR Urography Completed NCT00301470 Phase 4
4 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4 Silodosin;Placebo
5 Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplantation Completed NCT01631448 Phase 3
6 Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction Unknown status NCT01823575 Phase 2
7 Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
8 Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Completed NCT00250406 Phase 2
9 Randomized Controlled Trial of Cystocele Plication Risks ("CPR Trial"): A Pilot Study Completed NCT01197248 Phase 2
10 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
11 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer Completed NCT00002842 Phase 2 floxuridine;fluorouracil;leucovorin calcium
12 Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain Recruiting NCT02744430 Phase 2 Mirabegron
13 Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
14 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
15 Local Treatment With RP for Newly-diagnosed mPCa Unknown status NCT02138721 Not Applicable
16 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431 Not Applicable
17 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent Completed NCT00166361 Not Applicable
18 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
19 Laparoscopic Pyeloplasty Registry and Database Completed NCT00169650
20 Evaluating Ureteral Length Using Computed Tomography (CT) Completed NCT01542593 Not Applicable
21 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine Completed NCT00930046 Not Applicable
22 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877 Not Applicable
23 Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery Completed NCT00840996 Not Applicable Lidocaine;placebo
24 Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors Completed NCT02276924 Not Applicable
25 Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Recruiting NCT02419339
26 Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: Recruiting NCT03709992 Not Applicable Trospium Chloride;Tamsulosin
27 Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion Recruiting NCT03482089 Not Applicable
28 Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes Recruiting NCT02123082 Not Applicable
29 Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal Recruiting NCT02140970 Not Applicable Ibuprofen;Placebo
30 Nonabsorbable Versus Absorbable Sutures for Anterior Colporrhaphy Recruiting NCT03736811 Not Applicable
31 Renal Anhydramnios Fetal Therapy Recruiting NCT03101891 Not Applicable Isotonic fluid
32 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Enrolling by invitation NCT02160652
33 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position Not yet recruiting NCT03266770 Not Applicable
34 Ureteral Stent Versus Percutaneous Nephrostomy in Acutely Obstructed Infected Kidney Not yet recruiting NCT03498794 Not Applicable
35 CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome Not yet recruiting NCT02812212 Not Applicable
36 Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Terminated NCT02713633 Not Applicable
37 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO Withdrawn NCT00199472

Search NIH Clinical Center for Ureteral Obstruction

Cochrane evidence based reviews: ureteral obstruction

Genetic Tests for Ureteral Obstruction

Anatomical Context for Ureteral Obstruction

MalaCards organs/tissues related to Ureteral Obstruction:

42
Kidney, Cervix, Tongue, Endothelial, Colon, Liver, Cortex

Publications for Ureteral Obstruction

Articles related to Ureteral Obstruction:

(show top 50) (show all 1632)
# Title Authors Year
1
ClC-5 alleviates renal fibrosis in unilateral ureteral obstruction mice. ( 31054069 )
2019
2
Renal Fibrosis, Immune Cell Infiltration and Changes of TRPC Channel Expression after Unilateral Ureteral Obstruction in Trpc6-/- Mice. ( 31099508 )
2019
3
Anti-renal fibrosis effect of asperulosidic acid via TGF-β1/smad2/smad3 and NF-κB signaling pathways in a rat model of unilateral ureteral obstruction. ( 30668407 )
2019
4
The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction. ( 30884252 )
2019
5
pNaKtide ameliorates renal interstitial fibrosis through inhibition of sodium-potassium adenosine triphosphatase-mediated signaling pathways in unilateral ureteral obstruction mice. ( 29788096 )
2019
6
Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients. ( 29974220 )
2019
7
Ureteral stents for malignant extrinsic ureteral obstruction: outcomes and factors predicting stent failure. ( 30298199 )
2019
8
Protein kinase C inhibitor chelerythrine attenuates partial unilateral ureteral obstruction induced kidney injury in neonatal rats. ( 30439378 )
2019
9
Reversal Unilateral Ureteral Obstruction: A Mice Experimental Model. ( 30783029 )
2019
10
Iatrogenic Ureteral Obstruction During Transvaginal Oocyte Retrieval. ( 30785703 )
2019
11
Eplerenone Ameliorates Cell Pyroptosis in Contralateral Kidneys of Rats with Unilateral Ureteral Obstruction. ( 30799394 )
2019
12
Astaxanthin ameliorates renal interstitial fibrosis and peritubular capillary rarefaction in unilateral ureteral obstruction. ( 30816496 )
2019
13
Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice. ( 30818366 )
2019
14
Diagnostic utility of ultrasonography for detection of the cause and location of ureteral obstruction in cats: 71 cases (2010-2016). ( 30835178 )
2019
15
Clinical application of fluoroscopic guided percutaneous antegrade ureteral stents placement for the treatment of malignant ureteral obstruction. ( 30909269 )
2019
16
Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. ( 30918245 )
2019
17
Factors associated with postobstructive diuresis following decompressive surgery with placement of ureteral stents or subcutaneous ureteral bypass systems for treatment of ureteral obstruction in cats: 37 cases (2010-2014). ( 30938617 )
2019
18
Potential Role of the Resident Mesenchymal Stem-Like Cells in Renal Fibrogenesis after Ureteral Obstruction. ( 30949209 )
2019
19
Unilateral Ureteral Obstruction as a Model to Investigate Fibrosis-Attenuating Treatments. ( 30965656 )
2019
20
siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice. ( 30978213 )
2019
21
The antifibrotic and anti-inflammatory effects of icariin on the kidney in a unilateral ureteral obstruction mouse model. ( 30978648 )
2019
22
Correction: Role of the high-affinity leukotriene B4 receptor signaling in fibrosis after unilateral ureteral obstruction in mice. ( 30986278 )
2019
23
Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction. ( 30994838 )
2019
24
Protective effects of ghrelin on kidney tissue in rats with partial ureteral obstruction ( 30997983 )
2019
25
Klotho Inhibits Unilateral Ureteral Obstruction-Induced Endothelial-to-Mesenchymal Transition via TGF-β1/Smad2/Snail1 Signaling in Mice. ( 31024315 )
2019
26
Malignant ureteral obstruction: experience and comparative analysis of metallic versus ordinary polymer ureteral stents. ( 31039812 )
2019
27
Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction. ( 31071225 )
2019
28
Melatonin therapy protects against renal injury before and after release of bilateral ureteral obstruction in rats. ( 31100324 )
2019
29
Encrusted Cystitis with Suspected Ureteral Obstruction Following Cystoscopic-Guided Laser Ablation of Ectopic Ureters in a Dog. ( 29372865 )
2018
30
Effect of diabetes mellitus on the recovery of changes in renal functions and glomerular permeability following reversible 24-hour unilateral ureteral obstruction. ( 30592154 )
2018
31
As in Real Estate, Location Is What Matters: A Case Report of Transplant Ureteral Obstruction Due to an Inguinal Hernia. ( 29372065 )
2018
32
PEGylated pUR4/FUD peptide inhibitor of fibronectin fibrillogenesis decreases fibrosis in murine Unilateral Ureteral Obstruction model of kidney disease. ( 30356276 )
2018
33
Ureteral obstruction by sloughed tumor complicating cryoablation of a renal oncocytoma. ( 30533167 )
2018
34
Ureteral obstruction and ruptured kidney following ovarian hyperstimulation syndrome. ( 29391290 )
2018
35
Subcutaneous ureteral bypass for treatment of bilateral ureteral obstruction in a cat with retroperitoneal paraganglioma. ( 30311526 )
2018
36
Apoptosis-Associated Speck-Like Protein Containing a CARD Deletion Ameliorates Unilateral Ureteral Obstruction Induced Renal Fibrosis and Endoplasmic Reticulum Stress in Mice. ( 30057487 )
2018
37
Evaluating Renal Fibrosis with R2* Histogram Analysis of the Whole Cortex in a Unilateral Ureteral Obstruction Model. ( 30111497 )
2018
38
Deubiquitinase inhibitor PR-619 reduces Smad4 expression and suppresses renal fibrosis in mice with unilateral ureteral obstruction. ( 30114247 )
2018
39
HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model. ( 30161162 )
2018
40
Peroxidasin and Eosinophil Peroxidase, but not Myeloperoxidase, Contribute to Renal Fibrosis in the Murine Unilateral Ureteral Obstruction Model. ( 30565999 )
2018
41
Nrf2 deficiency promotes the progression from acute tubular damage to chronic renal fibrosis following unilateral ureteral obstruction. ( 29126308 )
2018
42
Longitudinal assessment of rabbit renal fibrosis induced by unilateral ureteral obstruction using two-dimensional susceptibility weighted imaging. ( 29236342 )
2018
43
Ablation of C/EBP homologous protein attenuates renal fibrosis after ureteral obstruction by reducing autophagy and microtubule disruption. ( 29425932 )
2018
44
Adenovirus-mediated P311 ameliorates renal fibrosis through inhibition of epithelial-mesenchymal transition via TGF-β1-Smad-ILK pathway in unilateral ureteral obstruction rats. ( 29436600 )
2018
45
The effect of darbepoetin alfa on renal fibrosis in rats with acute unilateral ureteral obstruction. ( 29521269 )
2018
46
Effects of cholecalciferol cholesterol emulsion on renal fibrosis and aquaporin 2 and 4 in mice with unilateral ureteral obstruction. ( 29602131 )
2018
47
Vimentin expression is required for the development of EMT-related renal fibrosis following unilateral ureteral obstruction in mice. ( 29631355 )
2018
48
Glomerular hyperpermeability after acute unilateral ureteral obstruction: effects of Tempol, NOS, RhoA, and Rac-1 inhibition. ( 29465305 )
2018
49
Application of resonance metallic stents for malignant ureteral obstruction. ( 29475395 )
2018
50
Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers. ( 29488389 )
2018

Variations for Ureteral Obstruction

Expression for Ureteral Obstruction

Search GEO for disease gene expression data for Ureteral Obstruction.

Pathways for Ureteral Obstruction

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 AGTR1 AGTR2 BMP7 EPO IL10 TGFB1
2
Show member pathways
12.93 AGTR1 AGTR2 BMP7 PTGS2 TGFB1 VEGFC
3
Show member pathways
12.41 AGTR1 CTNNB1 IL10 NOS2 TP53
4
Show member pathways
12.35 BMP7 CTNNB1 NOX4 TGFB1
5
Show member pathways
12.27 CTNNB1 NOS2 PTGS2 SPHK2
6
Show member pathways
12.13 IL10 NOS2 PTGS2 TGFB1
7
Show member pathways
12.1 BMP7 IL10 TGFB1 TP53 VEGFC
8 12.09 IL10 NOS2 SPHK2 TGFB1
9 11.98 CTNNB1 NOS2 PTGS2 TGFB1 TP53
10 11.95 AGTR1 CTNNB1 EPO NOS2 PTGS2 TGFB1
11 11.91 BMP7 CTNNB1 TGFB1 TP53
12 11.77 IL10 NOS2 TGFB1
13 11.74 NOS2 PTGS2 TP53
14 11.73 AGTR1 NOX4 TGFB1 VEGFC
15 11.73 NOS2 NOX4 PTGS2 TGFB1 TP53
16 11.72 PTGS2 TGFB1 VEGFC
17 11.61 IL10 NOS2 PTGS2 TGFB1 TP53
18 11.56 IL10 NOS2 PTGS2 TGFB1
19 11.54 BMP7 CTNNB1 TGFB1 TP53
20 11.46 EPO TP53 VEGFC
21 11.33 NOS2 PTGS2 TGFB1 TP53
22 11.18 NOS2 PTGS2 TP53
23 10.82 EPO NOS2 PTGS2 TP53

GO Terms for Ureteral Obstruction

Cellular components related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.02 AQP2 LRP2 NOX4 SLC12A1 SLC9A3

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 CTNNB1 IL10 PTGS2 TGFB1 VEGFC
2 cytokine-mediated signaling pathway GO:0019221 9.93 IL10 NOS2 PTGS2 TGFB1 TP53
3 regulation of apoptotic process GO:0042981 9.91 AGTR2 BMP7 CTNNB1 TGFB1 TP53
4 cell proliferation GO:0008283 9.91 CTNNB1 EPO LRP2 SPHK2 TGFB1 TP53
5 response to lipopolysaccharide GO:0032496 9.9 EPO IL10 NOS2 PTGS2
6 response to organic substance GO:0010033 9.83 IL10 PTGS2 TGFB1
7 regulation of inflammatory response GO:0050727 9.8 AGTR1 BRD4 PTGS2
8 aging GO:0007568 9.8 EPO IL10 NOX4 PTGS2 TGFB1
9 response to estradiol GO:0032355 9.78 BMP7 CTNNB1 PTGS2 TGFB1
10 negative regulation of cell cycle GO:0045786 9.77 BMP7 PTGS2 TGFB1
11 regulation of cell proliferation GO:0042127 9.77 AGTR1 CTNNB1 NOS2 PTGS2 TGFB1
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.76 BMP7 CTNNB1 TGFB1
13 epithelial to mesenchymal transition GO:0001837 9.74 BMP7 CTNNB1 TGFB1
14 positive regulation of apoptotic process GO:0043065 9.73 BMP7 CTNNB1 NOX4 PTGS2 TGFB1 TP53
15 response to hypoxia GO:0001666 9.72 EPO NOS2 NOX4 TGFB1 VEGFC
16 positive regulation of reactive oxygen species metabolic process GO:2000379 9.7 AGTR1 NOX4 TP53
17 positive regulation of cell proliferation GO:0008284 9.7 AGTR2 CTNNB1 EPO PTGS2 SPHK2 TGFB1
18 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.67 IL10 TGFB1 TP53
19 positive regulation of cellular protein metabolic process GO:0032270 9.66 AGTR1 TGFB1
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.66 BMP7 IL10
21 regulation of blood vessel diameter GO:0097746 9.65 AGTR1 AGTR2
22 morphogenesis of embryonic epithelium GO:0016331 9.65 CTNNB1 VEGFC
23 salivary gland morphogenesis GO:0007435 9.64 BMP7 TGFB1
24 angiotensin-activated signaling pathway GO:0038166 9.64 AGTR1 AGTR2
25 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 TGFB1 TP53
26 response to vitamin D GO:0033280 9.63 BMP7 PTGS2 TGFB1
27 regulation of protein import into nucleus GO:0042306 9.62 AGTR2 TGFB1
28 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.61 EPO PTGS2
29 renin-angiotensin regulation of aldosterone production GO:0002018 9.58 AGTR1 AGTR2
30 negative regulation of cell proliferation GO:0008285 9.5 BMP7 CTNNB1 IL10 NOX4 PTGS2 TGFB1
31 positive regulation of transcription, DNA-templated GO:0045893 9.23 AGTR2 BMP7 BRD4 CTNNB1 EPO IL10
32 negative regulation of apoptotic process GO:0043066 10.03 CTNNB1 EPO IL10 PTGS2 SPHK2 TP53
33 regulation of signaling receptor activity GO:0010469 10.02 BMP7 EPO IL10 TGFB1 VEGFC
34 inflammatory response GO:0006954 10.01 AGTR2 IL10 NOX4 PTGS2 TGFB1

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 BMP7 EPO IL10 TGFB1
2 protein binding GO:0005515 9.58 AGTR1 AGTR2 AQP2 BMP7 BRD4 CTNNB1
3 growth factor activity GO:0008083 9.56 BMP7 IL10 TGFB1 VEGFC
4 enzyme binding GO:0019899 9.55 BRD4 CTNNB1 PTGS2 TGFB1 TP53
5 angiotensin type II receptor activity GO:0004945 8.96 AGTR1 AGTR2

Sources for Ureteral Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....